EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect

Shuhei Kida, Makiko Suga, Yuta Yamaguchi, Shunya Ikeda, Yosuke Kogue, Ryuhei Kawamoto, Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, Emiko Mizuta, Yo Mizutani, Naoki Hosen

Cancer Immunology, Immunotherapy · 02.03.2026 · 75 (3)

DOI: 10.1007/s00262-026-04342-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 02.03.2026. Verfasst von Shuhei Kida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antibodies, Monoclonal, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR T cells targeting CLL-1 have shown antileukemia efficacy in patients with acute myeloid leukemia (AML). However, CLL-1low/- AML cells are present in some patients, suggesting that the development of CAR T cells with high sensitivity is necessary to eradicate all AML clones in these patients. Here, we identified CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody (mAb) that exhibited a significant anti-AML effect in vivo. We generated 13 new mAbs against CLL-1 and established CAR T cells from them. Of these, CAR T cells derived from mAb 2-23, which demonstrated greater affinity for CLL-1 than M26, the anti-CLL-1 mAb used in many previous studies, exhibited significant potential for cytokine production and cytotoxicity when co-cultured with AML cells. Treatment with 2-23 CAR T cells eradicated AML cells and significantly prolonged survival in AML xenograft models. Additionally, treatment with revumenib, a menin inhibitor, increased CLL-1 expression in AML cells harboring mixed-lineage leukemia (MLL) fusion genes or the NPM1 mutation, making them more susceptible to 2-23 CAR T cell-mediated cytotoxicity in vitro. These findings suggest that the clinical efficacy of CAR T cells derived from the novel, high-affinity anti-CLL-1 mAb 2-23 should be tested in patients with CLL-1-positive AML and also that combining 2-23 CAR T cells with revumenib may benefit some patients with CLL-1low/- AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntibodies, MonoclonalImmunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric AntigenHumansAnimalsMiceXenograft Model Antitumor AssaysNucleophosminMice, SCIDMice, Inbred NOD

Stichwörter der Autor:innen

AMLCAR T cellsCLL-1Menin inhibitorRevumenib

Substanzen

Antibodies, MonoclonalNucleophosminNPM1 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
  • Department of Hematology and Oncology, Osaka General Medical Center, Osaka, Japan.
  • Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Company, Ltd., Osaka, Japan.
  • Department of Clinical Laboratory and Biomedical Sciences, University of Osaka Graduate School of Medicine, Osaka, Japan.
  • Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.
  • World Premier International Immunology Frontier Research Center, University of Osaka, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Takeda Science Foundation

Zitieren

APA

Kida, S., Suga, M., Yamaguchi, Y., Ikeda, S., Kogue, Y., Kawamoto, R., Shibata, K., Tsutsumi, K., Murakami, H., Mizuta, E., Mizutani, Y., & Hosen, N. (2026). CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect. Cancer Immunology, Immunotherapy, 75(3). https://doi.org/10.1007/s00262-026-04342-x

Vancouver

Kida S, Suga M, Yamaguchi Y, Ikeda S, Kogue Y, Kawamoto R, et al. CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect. Cancer Immunology, Immunotherapy. 2026;75(3). doi:10.1007/s00262-026-04342-x

BibTeX
@article{Kida2026,
  author = {Kida, Shuhei and Suga, Makiko and Yamaguchi, Yuta and Ikeda, Shunya and Kogue, Yosuke and Kawamoto, Ryuhei and Shibata, Kumi and Tsutsumi, Kazuhito and Murakami, Hiraku and Mizuta, Emiko and Mizutani, Yo and Hosen, Naoki},
  title = {CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {3},
  doi = {10.1007/s00262-026-04342-x}
}
Kostenlos starten →